Trials / Completed
CompletedNCT00256191
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (planned)
- Sponsor
- Cortice Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material. The synthesis involves modification to the taxane side chain to overcome multidrug resistance and to achieve mutant tubulin binding. This study will be a multi-center, dose escalation, sequential group, Phase 1 study evaluating the intravenous administration of TPI 287 on an every 21 day cycle.
Detailed description
The primary objective of this study is to determine the maximum tolerated dose of TPI 287 administered every 21 days for Phase II clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TPI 287 Injection |
Timeline
- Start date
- 2005-11-01
- Completion
- 2007-02-01
- First posted
- 2005-11-21
- Last updated
- 2007-10-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00256191. Inclusion in this directory is not an endorsement.